FedEx Up Over 14%, on Pace for Largest Percent Increase Since September 1986 — Data Talk Update
FedEx Corporation (FDX) is currently at $293.87, up $37.49 or 14.62%
--Would be highest close since July 26, 2021, when it closed at $297.50
--On pace for largest percent increase since Sept. 29, 1986, when it rose 14.86%
--3rd largest one-day percentage gain on record
--Currently up four of the past five days
--Up 15.72% month-to-date; on pace for best month since March 2024, when it rose 16.38%
--Up 16.17% year-to-date
--Down 6.88% from its all-time closing high of $315.59 on May 27, 2021
--Up 18.29% from 52 weeks ago (June 28, 2023), when it closed at $248.44
--Would be a new 52-week closing high
--Up 28.93% from its 52-week closing low of $227.93 on Oct. 26, 2023
--Traded as high as $294.75; highest intraday level since July 26, 2021, when it hit $298.50
--Up 14.97% at today's intraday high; largest intraday percent increase since June 14, 2022, when it rose as much as 15.58%
--Best performer in the S&P 500 today
All data as of 12:14:11 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
June 26, 2024 12:35 ET (16:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks